QDDresearch

Simulations Plus, Inc. SLP

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 18.50 USD on Nov 1, 2026, +1.5% year to date

Quant rating

Quant rating D Rank 481 of 565 in Health Care
  1. Growth C 360 of 565
  2. Valuation D 441 of 565
  3. Quality C 304 of 565
  4. Revisions D 548 of 565
  5. Momentum C 311 of 565

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Growth and profitability

Growth and profitability by fiscal year
202520242023202220215Y avg
Revenue (mil)79.270.059.653.946.5–
Revenue growth13.1%17.5%10.5%16.0%11.7%13.7%
EPS (basic, normalized)−3.220.490.490.600.47–
EPS growth–0.0%−18.3%27.7%––
Gross margin58.4%61.6%80.5%79.9%77.2%71.5%
Net margin−81.7%14.2%16.7%23.2%21.1%−1.3%
ROE−42.1%5.6%5.7%7.3%6.1%−3.5%
Balance sheet, last quarter
Cash & short-term investments (mil)50.0
Current ratio5.54x
Long-term debt (mil)0
Net debt (mil)−50.0
Total equity (mil)139
Net debt / equity−0.36x
Net debt / EBITDA−2.28x

Estimates and valuation

Consensus estimates and implied multiples
Sales (mil)EBITDA (mil)EPS
Fiscal yearMean est.GrowthEV/SalesMean est.GrowthEV/EBITDAMean est.GrowthP/E
2025 actual 79.2+13.1%– 22.0+7.7%– −3.22−757.1%−5.7x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
SalesEPS
Fiscal yearEstimate (mil)1M3M6MEstimate1M3M6M
2026––––––––
2027––––––––
2028––––––––

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter endedFeb 2024May 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026May 2026
Sales reported (mil)18.318.518.718.922.420.417.518.424.321.9
Sales mean (mil)17.317.919.718.821.920.017.118.121.720.9
Surprise+5.9%+3.4%−5.5%+0.6%+2.3%+1.6%+2.4%+1.8%+12.1%+4.6%
EPS reported0.200.150.040.010.150.45−0.030.030.220.18
EPS mean0.190.150.040.110.150.11−0.050.130.200.13
Surprise+5.3%0.0%−9.1%−90.6%+1.7%+325.3%+40.0%−76.9%+11.4%+42.1%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
CompanyMarket capNet debt/EBITDANet marginP/BFY1 P/EFY2 P/EFY1 EV/EBITDAFY2 EV/EBITDA
SLP Simulations Plus, Inc.374M−2.28x−81.7%–––––
RGEN Repligen Corporation11.2B−2.19x6.6%4.80x85.3x66.6x63.0x44.5x
SOPH SOPHiA GENETICS SA650M1.10x−102.2%7.81x−8.4x−12.8x−19.6x−27.3x
VHI Vitalhub Corp354M−5.03x5.6%1.80x42.2x25.3x10.5x8.7x
TKNO Alpha Teknova, Inc.454M0.63x−42.6%6.31x−24.4x−28.5x−72.4x−145.4x
MXCT MaxCyte Inc164M−2.58x−135.1%1.06x−5.8x−6.2x−2.3x−2.8x
Mean−1.72x−58.2%4.36x17.8x8.9x−4.2x−24.5x
Median−2.23x−62.2%4.80x−5.8x−6.2x−2.3x−2.8x

Technical analysis

  • 1M+0.1%
  • 3M+0.9%
  • 1Y+1.0%
  • 3Y−45.3%

Financial statements in millions of USD

Income statement, Simulations Plus, Inc., fiscal years, most recent first
202520242023202220212020
Total revenue79.270.059.653.946.541.6
Cost of revenue33.026.911.610.810.610.6
Gross profit46.243.247.943.135.930.9
Selling, general & administrative expenses32.831.334.725.020.616.4
Research & development6.95.84.53.24.03.0
Interest expense (income), operating––––––
Unusual expense (income)76.6−1.60.70.30.50.2
Other operating expenses000000
Operating income−70.17.88.014.610.811.4
Net interest income (expense)0.74.63.70.50.30
Gain (loss) on sale of assets0000––
Other non-operating income (expense)000000
Net income before taxes−69.412.411.715.111.111.4
Provision for taxes−4.72.51.72.61.32.1
Minority interest––––––
Equity in affiliates––––––
U.S. GAAP adjustment––––––
Net income before extraordinary items−64.710.010.012.59.89.3
Extraordinary items––––––
Net income−64.710.010.012.59.89.3
EBIT, normalized6.56.18.714.911.311.6
EBITDA, normalized14.611.812.418.414.814.6
Basic EPS, normalized−3.220.490.490.600.47–

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.